AAREYDRUGS
Aarey Drugs & Pharmaceuticals financials
- Market cap
- ₹296 Cr
- Sector
- Healthcare
What Aarey Drugs & Pharmaceuticals Limited does
Aarey Drugs & Pharmaceuticals manufactures bulk-drug intermediates — Mono Methyl Urea, Di Methyl Urea, Ortho Para Nitro Anisole, 2-Bromomethyl-1,3-Dioxalane and Uracil — and Active Pharmaceutical Ingredients (APIs) including Metformin HCL, Mefenamic Acid and Doxophylline. Alongside manufacturing, the company also imports and trades in solvents and chemicals. All manufacturing is carried out at its single works/factory in Tarapur MIDC, Boisar, Maharashtra.
Segments
- Bulk-drug intermediates
- Active Pharmaceutical Ingredients (API)
- Solvents & chemicals trading
- Manufacturing facility
- 1 (Tarapur MIDC, Boisar, Maharashtra)
- Bulk-drug intermediates manufactured
- 5 (Mono Methyl Urea, Di Methyl Urea, Ortho Para Nitro Anisole, 2-Bromomethyl-1,3-Dioxalane, Uracil)
- APIs manufactured
- 3 (Metformin HCL, Mefenamic Acid, Doxophylline)
Quarterly results
Q1 FY27: revenue down 56.3%, net profit down 25.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 105 | 134 | 108 | 102 | 84 −20% | 96 −28% | 189 +75% | 45 −56% |
| EBITDA | 4 | 2 | -4 | 2 | 3 −29% | -2 −169% | 4 +203% | 1 −23% |
| Net profit | 2 | 1 | 0 | 1 | 1 −36% | 1 −21% | 2 +232% | 1 −26% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +36.0% 1Y
1Y: ₹72.69 on 10 Sept 2025 → ₹98.89. High ₹99.98 (9 Sept 2026), low ₹50.75 (30 Mar 2026).
Financials, as filed
Revenue grew 9.3% a year over 2 years, FY24 to FY26. Operating margin held at 1.5%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹396 Cr | ₹474 Cr | ₹472 Cr |
| Operating profit | ₹4 Cr | ₹3 Cr | ₹7 Cr |
| Operating margin | 1.1% | 0.6% | 1.5% |
| Interest | ₹2 Cr | ₹3 Cr | ₹5 Cr |
| Depreciation | ₹4 Cr | ₹3 Cr | ₹3 Cr |
| Net profit | ₹5 Cr | ₹4 Cr | ₹5 Cr |
| Net margin | 1.3% | 0.9% | 1.0% |
| Cash from operations | ₹-3 Cr | ₹10 Cr | ₹10 Cr |
| Free cash flow | ₹-4 Cr | ₹5 Cr | ₹-2 Cr |
| ROCE | 6.0% | 6.0% | 6.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹23 Cr | ₹25 Cr | ₹25 Cr | ₹28 Cr | ₹28 Cr | ₹28 Cr |
| Reserves | ₹75 Cr | ₹88 Cr | ₹92 Cr | ₹105 Cr | ₹120 Cr | ₹122 Cr |
| Borrowings | ₹18 Cr | ₹14 Cr | ₹38 Cr | ₹31 Cr | ₹51 Cr | ₹50 Cr |
| Other liabilities | ₹116 Cr | ₹117 Cr | ₹136 Cr | ₹139 Cr | ₹94 Cr | ₹97 Cr |
| Total liabilities | ₹233 Cr | ₹245 Cr | ₹291 Cr | ₹303 Cr | ₹294 Cr | ₹297 Cr |
| Fixed assets | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹13 Cr | ₹25 Cr | ₹26 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr |
| Other assets | ₹218 Cr | ₹230 Cr | ₹277 Cr | ₹289 Cr | ₹267 Cr | ₹269 Cr |
| Total assets | ₹233 Cr | ₹245 Cr | ₹291 Cr | ₹303 Cr | ₹294 Cr | ₹297 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Aug 2026
Since Sep 2025, FIIs added +3.28 pp while the public trimmed −2.76 pp. The shareholder count shrank 10% to 13,480.
- Promoters
- 42.8%
- FIIs
- 4.4%
- DIIs
- 1.5%
- Public
- 51.3%
Since Sep 2025
- FIIs +3.28 pp
- Public −2.76 pp
- Promoters −2.01 pp
How it drifted, 12 quarters
Over this window promoters fell from 50.0% to 42.8% — −7.3 pp.
Ownership split by quarter, oldest first. Dec '23: Promoters 50.0%, FIIs 3.8%, Public 46.1%.Mar '24: Promoters 45.3%, FIIs 3.4%, Public 51.3%.Jun '24: Promoters 45.3%, FIIs 3.4%, Public 51.3%.Sep '24: Promoters 45.4%, FIIs 2.8%, Public 51.8%.Dec '24: Promoters 44.8%, FIIs 2.3%, Public 52.9%.Mar '25: Promoters 44.8%, FIIs 2.3%, Public 52.9%.Jun '25: Promoters 44.8%, FIIs 2.0%, Public 53.2%.Sep '25: Promoters 44.8%, FIIs 1.1%, Public 54.1%.Dec '25: Promoters 39.0%, FIIs 3.9%, Public 57.1%.Mar '26: Promoters 37.7%, FIIs 4.2%, DIIs 1.6%, Public 56.5%.Jun '26: Promoters 37.7%, FIIs 4.8%, DIIs 1.6%, Public 55.9%.Aug '26: Promoters 42.8%, FIIs 4.4%, DIIs 1.5%, Public 51.3%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Ekta Nimit Ghatalia +1.62 pp 1.62% held
- Nimit Rajesh Ghatalia +1.28 pp 5.34% held
- Mihir Rajesh Ghatalia Huf +0.79 pp 0.79% held
- Mira Mihir Ghatalia +0.61 pp 3.04% held
- Rajesh Pranlal Ghatalia +0.58 pp 0.59% held
- Bina Rajesh Ghatalia +0.47 pp 14.59% held
- Mihir Rajesh Ghatalia +0.30 pp 10.30% held
The same filing shows 7 holders trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Aug 2026 filing
Every holder of Aarey Drugs & Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Bina Rajesh Ghatalia | 14.59% | +0.47 pp |
| Mihir Rajesh Ghatalia | 10.30% | +0.30 pp |
| Nimit Impex | 6.51% | −0.58 pp |
| Nimit Rajesh Ghatalia | 5.34% | +1.28 pp |
| Mira Mihir Ghatalia | 3.04% | +0.61 pp |
| Elysian Wealth Fund FPI fund | 2.87% | −0.25 pp |
| Krishnamurthy C G | 1.62% | −0.14 pp |
| Ekta Nimit Ghatalia | 1.62% | +1.62 pp |
| Suvi Rubber Pvt Ltd | 1.52% | −0.13 pp |
| Shree Salasar Properties And Finance Private Limited Corporate | 1.49% | −0.13 pp |
| Chetan Kirtibhai Mehta | 1.30% | −0.11 pp |
| Richa Bothra | 1.25% | −0.11 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Aarey Drugs & Pharmaceuticals Limited
Guides on how to read this kind of business and the numbers that matter.